Publication | Open Access

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling

Effective Cell-based BlockadeSignaling PathwayNovel TherapyMedicineReceptor Tyrosine KinaseImmunologyImmune Checkpoint InhibitorPharmacologyCell BiologyCell SignalingTumor MicroenvironmentJak-stat Signaling Pathway